Vaporox Inc.

Vaporox Inc. manufactures and distributes the Vaporous Hyperoxia Therapy (VHT) system, an FDA-cleared advanced wound care device designed to accelerate healing of chronic wounds including diabetic foot ulcers, pressure injuries, sacral wounds, and venous leg ulcers. The VHT system delivers a combination of ultrasonic hydrating mist and concentrated oxygen to promote angiogenesis, improve wound hygiene, and stimulate tissue regeneration. The device is primarily deployed in skilled nursing facilities (SNFs), long-term care facilities, wound care clinics, and podiatry practices. Vaporox operates under a pay-per-use model with no capital investment required; treatment is covered by Medicare. Clinical outcomes from real-world SNF data demonstrate 88% wound healing rates, with 87% closure probability within 12 weeks and a median of 9.5 treatments to closure. The company emphasizes operational feasibility and integration into existing wound care protocols. Product efficacy is further supported when combined with standard wound care (SWC), achieving 84% healing rates. Vaporox has established strategic partnerships, including a collaboration with MIMEDX to expand provider adoption. The device is suitable for medically complex, elderly populations and demonstrates effectiveness even in cases that have failed prior interventions such as grafts, hyperbaric oxygen therapy (HBOT), and negative pressure wound therapy (NPWT). All marketing materials and clinical presentations target B2B healthcare procurement and clinical decision-makers.